financetom
Business
financetom
/
Business
/
Cybersecurity company CyberArk to acquire Venafi in $1.5 bln deal
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Cybersecurity company CyberArk to acquire Venafi in $1.5 bln deal
May 20, 2024 4:39 AM

May 20 (Reuters) - CyberArk said on Monday it

will acquire cybersecurity firm Venafi from equity firm Thoma

Bravo in a deal valued at around $1.54 billion.

The firm will acquire Venafi in a combination of $1 billion

in cash and around $540 million in stock, and expects the deal

to close in the second half of 2024.

Venafi is also expected to add around $150 million in

annual recurring revenue and will be accretive to CyberArk's

margins immediately, the company said.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
SEALSQ to Acquire 30% Stake in WeCanGroup
SEALSQ to Acquire 30% Stake in WeCanGroup
Mar 24, 2025
04:27 AM EDT, 03/24/2025 (MT Newswires) -- SEALSQ ( LAES ) has agreed to acquire a 30% equity interest in blockchain technology firm WeCanGroup, the companies said Monday. SEALSQ ( LAES ), its parent WISeKey, and WeCanGroup will integrate their Web 3.0 and post-quantum cryptographic technologies under the terms of the deal. SEALSQ ( LAES ) shares were up 6.7%...
DBV Technologies' Peanut Allergy Patch Clears FDA Safety Hurdle for Children
DBV Technologies' Peanut Allergy Patch Clears FDA Safety Hurdle for Children
Mar 24, 2025
04:21 AM EDT, 03/24/2025 (MT Newswires) -- DBV Technologies ( DBVT ) said Monday the US Food and Drug Administration has agreed with the company's proposal that the safety exposure data from the its phase 3 study for Viaskin peanut patch in four- to seven-year-olds will be enough to support a biologics license application filing in this age group. The...
Opthea's Phase 3 Eye Therapy Trial Fails to Meet Primary Endpoint
Opthea's Phase 3 Eye Therapy Trial Fails to Meet Primary Endpoint
Mar 24, 2025
04:21 AM EDT, 03/24/2025 (MT Newswires) -- Opthea ( OPT ) said Monday the phase 3 study of its experimental drug, sozinibercept in combination with aflibercept to treat patients with wet age-related macular degeneration, did not meet its primary endpoint. Following the results, Opthea ( OPT ) said it is evaluating its obligations under its development funding agreement with investors,...
MOVES-Bank of America set to appoint Vikram Sahu as new country head for India
MOVES-Bank of America set to appoint Vikram Sahu as new country head for India
Mar 24, 2025
MUMBAI, March 24 (Reuters) - Bank of America Corp ( BAC ) is set to appoint Vikram Sahu as the new country executive for its India business, according to a memo reviewed by Reuters. Sahu, who is currently head of global equity research based out of New York, will replace Kaku Nakhate as the India country executive. Sahu will move...
Copyright 2023-2026 - www.financetom.com All Rights Reserved